Osteoporosis :: Aclasta Reclast prevents additional fractures in hip fracture patients with osteoporosis

Results of the first-ever clinical study in patients with osteoporosis who suffered a hip fracture show that a once-yearly infusion of Aclasta®/Reclast® (zoledronic acid 5 mg)[*] reduced the risk of subsequent fractures by 35% compared to patients treated with placebo.

Blood Pressure :: FDA approves first generic versions of Coreg to treat high blood pressure

The U.S. Food and Drug Administration today approved the first generic versions of Coreg (carvedilol). Coreg is a widely used medication that is FDA-approved to treat high blood pressure, mild to severe chronic heart failure and left ventricular dysfunction following a heart attack.

Leukemia :: Heart failure is rare among leukemia patients on imatinib

Congestive heart failure rarely occurs among leukemia patients who take imatinib, researchers at the University of Texas M. D. Anderson Cancer Center found after an exhaustive review of the detailed medical histories of 1,276 patients who enrolled in clinical trials for the drug.